Cargando…

Neurological Toxicity in Metastatic Colorectal Cancer Patients Treated with Modified FOLFOX6 Plus Bevacizumab

This study was conducted to investigate the toxicity and efficacy of modified FOLFOX6 plus bevacizumab in patients with metastatic colorectal cancer with particular regard to oxaliplatin-induced neuropathy. Toxicity was graded according to the National Cancer Institute Common Terminology Criteria fo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Otsu, Satoshi, Hirashima, Yoshinori, Nishikawa, Kazuo, Sakashita, Hiroyuki, Morinaga, Ryotaro, Watanabe, Koichiro, Shirao, Kuniaki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Libertas Academica 2014
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4134004/ https://www.ncbi.nlm.nih.gov/pubmed/25210489 http://dx.doi.org/10.4137/JCM.S15553

Ejemplares similares

Vesicocutaneous fistula formation during treatment with sunitinib malate: Case report
por: Watanabe, Koichiro, et al.
Publicado: (2010)

Febrile Neutropenia in a Patient with Non-Small Cell Lung Cancer Treated with the Immune-Checkpoint Inhibitor Nivolumab
por: Hisamatsu, Yasushi, et al.
Publicado: (2020)

Pathological Evaluation of Resected Colorectal Liver Metastases: mFOLFOX6 Plus Bevacizumab versus mFOLFOX6 Plus Cetuximab in the Phase II ATOM Trial
por: Takahashi, Takao, et al.
Publicado: (2022)

Perioperative FOLFOX4 plus bevacizumab for initially unresectable advanced colorectal cancer (NAVIGATE-CRC-01)
por: Suenaga, Mitsukuni, et al.
Publicado: (2015)

The McCAVE Trial: Vanucizumab plus mFOLFOX‐6 Versus Bevacizumab plus mFOLFOX‐6 in Patients with Previously Untreated Metastatic Colorectal Carcinoma (mCRC)
por: Bendell, Johanna C., et al.
Publicado: (2019)

FOLFOX‐bevacizumab chemotherapy in patients with metastatic neuroendocrine tumors
por: Lacombe, Caroline, et al.
Publicado: (2023)

Bevacizumab plus FOLFIRI or FOLFOX in chemotherapy-refractory patients with metastatic colorectal cancer: a retrospective study
por: Lièvre, Astrid, et al.
Publicado: (2009)

Bevacizumab plus FOLFOX or FOLFIRI regimens on patients with unresectable liver-only metastases of metastatic colorectal cancer
por: Mehrzad, Valiollah, et al.
Publicado: (2016)

Overweight is associated with better prognosis in metastatic colorectal cancer patients treated with bevacizumab plus FOLFOX chemotherapy
por: Cybulska-Stopa, Bożena, et al.
Publicado: (2020)

Randomised phase II trial of mFOLFOX6 plus bevacizumab versus mFOLFOX6 plus cetuximab as first-line treatment for colorectal liver metastasis (ATOM trial)
por: Oki, Eiji, et al.
Publicado: (2019)

A Randomized, Open-Label, Multicenter, Phase 3 Study of High-Dose Vitamin C Plus FOLFOX ± Bevacizumab versus FOLFOX ± Bevacizumab in Unresectable Untreated Metastatic Colorectal Cancer (VITALITY Study)
por: Wang, Feng, et al.
Publicado: (2022)

Rationale and design of the TRUSTY study: a randomised, multicentre, open-label phase II/III study of trifluridine/tipiracil plus bevacizumab versus irinotecan, fluoropyrimidine plus bevacizumab as second-line treatment in patients with metastatic colorectal cancer progressive during or following first-line oxaliplatin-based chemotherapy
por: Yoshino, Takayuki, et al.
Publicado: (2018)

FOLFOXIRI plus bevacizumab versus FOLFOX plus bevacizumab for patients with metastatic colorectal cancer and ≥3 circulating tumour cells: the randomised phase III VISNÚ-1 trial
por: Aranda, Enrique, et al.
Publicado: (2020)

Cediranib with mFOLFOX6 vs bevacizumab with mFOLFOX6 in previously treated metastatic colorectal cancer
por: Cunningham, D, et al.
Publicado: (2013)

Acute Myocardial Infarction Due to Coronary Artery Embolism during Chemotherapy with mFOLFOX-6 Plus Bevacizumab for Metastatic Colon Cancer
por: Aoshima, Hiroyuki, et al.
Publicado: (2022)

A Case of High-Grade Neuroendocrine Carcinoma That Improved with Bevacizumab plus Modified FOLFOX6 as the Fourth-Line Chemotherapy
por: Takeuchi, Satoshi, et al.
Publicado: (2011)

S-1 and oxaliplatin (SOX) plus bevacizumab versus mFOLFOX6 plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer: updated overall survival analyses of the open-label, non-inferiority, randomised phase III: SOFT study
por: Baba, Hideo, et al.
Publicado: (2017)

Successful Treatment of Metastatic Anal Canal Adenocarcinoma with mFOLFOX6 + Bevacizumab
por: Matsunaga, Mototsugu, et al.
Publicado: (2016)

Bevacizumab Plus FOLFOX-4 Combined With Deep Electro-Hyperthermia as First-line Therapy in Metastatic Colon Cancer: A Pilot Study
por: Ranieri, Girolamo, et al.
Publicado: (2020)

Randomized, Phase II study of pemetrexed plus bevacizumab versus pemetrexed alone after treatment with cisplatin, pemetrexed, and bevacizumab in advanced non‐squamous, non‐small cell lung cancer: TORG (thoracic oncology research group) 1321
por: Kasai, Takashi, et al.
Publicado: (2023)

Atypical Reversible Leucoencephalopathy Syndrome after Bevacizumab/Folfox Regimen for Metastatic Colon Cancer
por: Salmi, Narimane, et al.
Publicado: (2014)

Modified FOLFOX-6 Plus Bevacizumab Chemotherapy for Metastatic Colorectal Cancer in Patients Receiving Hemodialysis: A Report of Three Cases and Review of the Literature
por: Funasaka, Chikako, et al.
Publicado: (2019)

Corrigendum: Bevacizumab Plus FOLFOX-4 Combined With Deep Electro-Hyperthermia as First-line Therapy in Metastatic Colon Cancer: A Pilot Study
por: Ranieri, Girolamo, et al.
Publicado: (2021)

Pathological complete response after preoperative chemotherapy including FOLFOX plus bevacizumab for locally advanced rectal cancer: A case report and literature review
por: Miyamoto, Ryoichi, et al.
Publicado: (2019)

A Case of Appendiceal Adenocarcinoma with Clinical Benefit from FOLFOX and Bevacizumab
por: Powell, Erin D., et al.
Publicado: (2009)

S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer (TRICOLORE): a randomized, open-label, phase III, noninferiority trial
por: Yamada, Y, et al.
Publicado: (2018)

Cost-effectiveness of FOLFOX6+Bevacizumab Versus FOLFOX6+Cetuximab in Stage IV Colorectal Cancer Patients in Shiraz, Iran
por: Jafari, Abdosaleh, et al.
Publicado: (2023)

Phase II clinical study of modified FOLFOX7 (intermittent oxaliplatin administration) plus bevacizumab in patients with unresectable metastatic colorectal cancer—CRAFT study
por: Tezuka, Tohru, et al.
Publicado: (2013)

MicroRNAs as outcome predictors in patients with metastatic colorectal cancer treated with bevacizumab in combination with FOLFOX
por: Kiss, I., et al.
Publicado: (2017)

Metastatic Urothelial Carcinoma with Glandular Differentiation That Confirmed the Response by Autopsy Specimen to Second-Line mFOLFOX6 (Fluorouracil, Oxaliplatin, and Leucovorin) plus Bevacizumab Chemotherapy
por: Naiki, Taku, et al.
Publicado: (2017)

Molecular markers of response and toxicity to FOLFOX chemotherapy in metastatic colorectal cancer
por: Chua, W, et al.
Publicado: (2009)

5-Fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) plus sunitinib or bevacizumab as first-line treatment for metastatic colorectal cancer: a randomized Phase IIb study
por: Hecht, J Randolph, et al.
Publicado: (2015)

FOLFOX6 and bevacizumab in non-optimally resectable liver metastases from colorectal cancer
por: Bertolini, F, et al.
Publicado: (2011)

Case Report: Atezolizumab plus bevacizumab for combined hepatocellular-cholangiocarcinoma
por: Satake, Tomoyuki, et al.
Publicado: (2023)

Protocol of a randomised phase III clinical trial of sequential capecitabine or 5-fluorouracil plus bevacizumab (Cape/5-FU-Bmab) to capecitabine or 5-fluorouracil plus oxaliplatin plus bevacizumab (CapeOX/mFOLFOX6-Bmab) versus combination CapeOX/mFOLFOX6-Bmab in advanced colorectal cancer: the C-cubed (C(3)) study
por: Nagasaka, Takeshi, et al.
Publicado: (2016)

A Phase II Clinical Study of mFOLFOX6 Plus Bevacizumab as First-line Therapy for Japanese Advanced/Recurrent Colorectal Cancer Patients
por: Nishina, Tomohiro, et al.
Publicado: (2013)

A 5-year recurrence-free survivor with over ten colorectal liver metastases undergoing FOLFOX plus bevacizumab followed by two-stage hepatectomy
por: Tamaoki, Yuka, et al.
Publicado: (2015)

Complete pathological response in a patient with multiple liver metastases from colon cancer treated with Folfox-6 chemotherapy plus bevacizumab: a case report
por: Malavasi, Norma, et al.
Publicado: (2009)

Intraperitoneal paclitaxel combined with FOLFOX/CAPOX plus bevacizumab for colorectal cancer with peritoneal carcinomatosis (the iPac-02 trial): study protocol of a single arm, multicenter, phase 2 study
por: Murono, Koji, et al.
Publicado: (2023)

mFOLFOX6 plus bevacizumab to treat liver-only metastases of colorectal cancer that are unsuitable for upfront resection (TRICC0808): a multicenter phase II trial comprising the final analysis for survival
por: Yasuno, Masamichi, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_jkpeset7tqigvbl6tjj5te1mau